BROOKLINE, Mass.--(BUSINESS WIRE)--Advanced Aesthetic Technologies, Inc. (ATT), the leader in aesthetic gel implant technology, today announced new financing on Netcapital private securities platform. AAT’s Algeness® product line of all-natural gel dermal fillers is poised to enter the US aesthetic market after successfully launching in 33 countries in Europe, Asia, Middle East, and South America.
According to AAT Executive Chairman, Richard Burtt, “We have selected the Netcapital funding platform to reach a broader investment audience and efficiently raise financing for the necessary US FDA clinical study and further development of our gel implant technology. Netcapital has demonstrated its ability for technology and healthcare businesses to reach the global investor community effectively and cost efficiently.“
About the Aesthetic Industry
According to Market Research Future, the global dermal fillers market is expected to grow at a compound annual growth rate of 12.5% over the next five years and is expected to reach $10 billion by 2023. The major factors driving the growth of this market are increased demand by both practitioners and consumers towards the use of minimally invasive and non-invasive procedures.
Worldwide, 7-8 million filler procedures are performed annually by plastic surgeons, dermatologists and other practitioners. In the US alone, plastic surgeons performed nearly 3.5 million Hyaluronic Acid filler procedures in 2016, representing over 25% of the non-surgical procedures performed by these surgeons.(1)
Netcapital is a private securities platform that makes capital markets work for real people. The portal connects investors to entrepreneurs to help private companies grow. Netcapital enables companies to raise capital by selling common stock to investors, thereby empowering emerging companies to raise capital through investment opportunities to the public. The Netcapital funding portal is registered with the U.S. Securities and Exchange Commission (SEC) and is a member of the Financial Industry Regulatory Authority (FINRA), a registered national securities association, as required by SEC rules.
Algeness is the all-natural, biodegradable, biocompatible agarose-based gel implant, free of all synthetic or cross-linking chemicals; and proven through multiple clinical studies in Europe. The uniqueness of Algeness dermal fillers is its abilities to add immediate volume in the facial area with excellent persistence without the added cross-linked chemicals required by all Hyaluronic Acid fillers. Algeness is formulated in several injectable concentrations to match specific cosmetic improvements of the lips, fine lines, and the folds around the mouth and for shaping and volumizing the cheeks, jawline and other areas. With the CE Mark certification, Algeness is available in 33 countries in Europe, South America, Asia, and the Middle East.
To learn more about the Algeness offering visit: https://netcapital.com/companies/aat
(1) 2016 International Study of Cosmetic Surgery, International Society of Aesthetic Plastic Surgery
Algeness ® and Master Your Results® are registered trademarks of AAT, Inc. and its subsidiary Algeness-Europe Ltd, Ireland.